Astellas Pharma is focusing on diversification, with its portfolio spanning cancer, vision loss and menopause treatments. Its Chief Medical Officer, Tadaaki Taniguci, said the company was also expanding its gene therapy output, using acquisitions and licensing to build capability, while in oncology, the firm’s lead drugs include treatments for prostate and bladder cancer. Astellas is also testing a small molecule for treating menopause symptoms.

Akira Ransomware Exploits SonicWall VPNs in Likely Zero-Day Attack on Fully-Patched Devices
SonicWall SSL VPN devices have become the target of Akira ransomware attacks as part of a newfound surge in activity observed in late July 2025.